Doximity
DOCS
Market cap $11.4B

60.20 USD

+0.12

0.20%

At close Jul 11, 4:00 PM EDT

After hours

60.13

-0.07

0.12%

1 day

0.20%

5 days

-2.23%

1 month

4.75%

3 months

13.91%

6 months

21.10%

Year to date

12.40%

1 year

122.22%

5 years

13.58%

10 years

13.58%

About: Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.

Employees: 830

Healthcare Health Information Services

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 13 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

127% more first-time investments, than exits

New positions opened: 111 | Existing positions closed: 49

47% more repeat investments, than reductions

Existing positions increased: 196 | Existing positions reduced: 133

25% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 5 (+1) [Q1 2025]

18% more capital invested

Capital invested by funds: $6.18B [Q4 2024] → $7.28B (+$1.1B) [Q1 2025]

13% more funds holding

Funds holding: 427 [Q4 2024] → 482 (+55) [Q1 2025]

3.64% more ownership

Funds ownership: 90.32% [Q4 2024] → 93.96% (+3.64%) [Q1 2025]

7% less call options, than puts

Call options by funds: $101M | Put options by funds: $109M

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$50

17%

downside

Avg. target

$62

4%

upside

High target

$80

33%

upside

13 analyst ratings

6 positive

46%

7 neutral

54%

0 negative

0%

Evercore ISI Group Elizabeth Anderson	16%upside $70	Outperform Upgraded	9 Jul 2025
B of A Securities Allen Lutz	3%upside $62	Neutral Maintained	25 Jun 2025
BTIG David Larsen	33%upside $80	Buy Upgraded	2 Jun 2025
JP Morgan Anne Samuel	0%downside $60	Neutral Maintained	27 May 2025
Goldman Sachs David Roman	17%downside $50	Neutral Maintained	21 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about DOCS published over the past 30 days

Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Doximity Crushes The Rule Of 40 - Try Rule Of 58

I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation.

Doximity Crushes The Rule Of 40 - Try Rule Of 58

Zacks Investment Research

Doximity (DOCS) Laps the Stock Market: Here's Why

Doximity (DOCS) concluded the recent trading session at $61.09, signifying a +1.13% move from its prior day's close.

Doximity (DOCS) Laps the Stock Market: Here's Why

Zacks Investment Research

Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?

DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.

Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?

Zacks Investment Research

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.

Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?

Zacks Investment Research

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.

DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?

Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'

I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook.

Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'

Zacks Investment Research

OGN or DOCS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?

OGN or DOCS: Which Is the Better Value Stock Right Now?

Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm

Zacks Investment Research

DOCS Boosts Client Retention via Workflow Integration and AI Tools

Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.

DOCS Boosts Client Retention via Workflow Integration and AI Tools

See News Rankings

Charts implemented using Lightweight Charts™